Name | Capital Health Home Care |
---|---|
Location | 1100 Lake Avenue, Ashtabula, Ohio |
Certified By | Medicare |
Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Home Health Aide |
Medicare ID | 367251 |
Ownership Type | Proprietary |
Service Area Zip Codes | 44003, 44004, 44005, 44010, 44021, 44022, 44023, 44024, 44026, 44030, 44032, 44040, 44041, 44047, 44048, 44057, 44060, 44062, 44065, 44068, 44073, 44076, 44077, 44081, 44082, 44084, 44085, 44086, 44092, 44093, 44094, 44095, 44099, 44108, 44110, 44117, 44118, 44119, 44121, 44122, 44123, 44124, 44132, 44143, 44402, 44403, 44404, 44410, 44417, 44418, 44420, 44425, 44428, 44437, 44438, 44440, 44444, 44446, 44450, 44470, 44473, 44481, 44482, 44483, 44484, 44485, 44491, 44504, 44505, 44512, 44515 |
NPI Number | 1083725576 |
Organization Name | CONTINUUM HOME CARE, INC. |
Address | 1100 Lake Ave, Ashtabula, OH 44004 |
Phone Number | 440-964-3332 |
News Archive
Gilead Sciences, Inc. and Arresto Biosciences, Inc., a privately-held, development-stage biotechnology company focused on medicines to treat fibrotic diseases and cancer, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Arresto. Under the terms of the agreement, Gilead will acquire Arresto for $225 million and potential future payments based on achievement of certain sales levels.
Disorders of blood cells may begin in the biological environment where the cells develop, not just with the cells themselves, according to a study from researchers at the Massachusetts General Hospital (MGH) and the Peter MacCallum Cancer Center (Peter Mac) in Melbourne, Australia.
Food advertising is a multi-billion dollar industry, with approximately $1.8 billion annually aimed at children and adolescents, who view between 1,000 and 2,000 ads per year.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).
Peripheral artery disease (PAD) is a progressive and costly disease, but remains under-diagnosed and under treated. While current PAD treatments are effective at clearing artery blockages in the lower leg, high recurrence rates and the subsequent need for repeat procedures are costly. Even after initial procedures to clear blockages in leg arteries, hospitalizations and associated costs in patients with peripheral artery disease increase as the condition progresses, according to research reported in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
› Verified 3 days ago
NPI Number | 1922309731 |
Organization Name | CHS OF ASHTABULA INC |
Doing Business As | CONTINUUM HOME CARE |
Address | 1100 Lake Ave, Ashtabula, OH 44004 |
Phone Number | 440-964-3332 |
News Archive
Gilead Sciences, Inc. and Arresto Biosciences, Inc., a privately-held, development-stage biotechnology company focused on medicines to treat fibrotic diseases and cancer, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Arresto. Under the terms of the agreement, Gilead will acquire Arresto for $225 million and potential future payments based on achievement of certain sales levels.
Disorders of blood cells may begin in the biological environment where the cells develop, not just with the cells themselves, according to a study from researchers at the Massachusetts General Hospital (MGH) and the Peter MacCallum Cancer Center (Peter Mac) in Melbourne, Australia.
Food advertising is a multi-billion dollar industry, with approximately $1.8 billion annually aimed at children and adolescents, who view between 1,000 and 2,000 ads per year.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).
Peripheral artery disease (PAD) is a progressive and costly disease, but remains under-diagnosed and under treated. While current PAD treatments are effective at clearing artery blockages in the lower leg, high recurrence rates and the subsequent need for repeat procedures are costly. Even after initial procedures to clear blockages in leg arteries, hospitalizations and associated costs in patients with peripheral artery disease increase as the condition progresses, according to research reported in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
› Verified 3 days ago
Quality Rating: |
News Archive
Gilead Sciences, Inc. and Arresto Biosciences, Inc., a privately-held, development-stage biotechnology company focused on medicines to treat fibrotic diseases and cancer, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Arresto. Under the terms of the agreement, Gilead will acquire Arresto for $225 million and potential future payments based on achievement of certain sales levels.
Disorders of blood cells may begin in the biological environment where the cells develop, not just with the cells themselves, according to a study from researchers at the Massachusetts General Hospital (MGH) and the Peter MacCallum Cancer Center (Peter Mac) in Melbourne, Australia.
Food advertising is a multi-billion dollar industry, with approximately $1.8 billion annually aimed at children and adolescents, who view between 1,000 and 2,000 ads per year.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).
Peripheral artery disease (PAD) is a progressive and costly disease, but remains under-diagnosed and under treated. While current PAD treatments are effective at clearing artery blockages in the lower leg, high recurrence rates and the subsequent need for repeat procedures are costly. Even after initial procedures to clear blockages in leg arteries, hospitalizations and associated costs in patients with peripheral artery disease increase as the condition progresses, according to research reported in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
› Verified 3 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often the home health team began their patients’ care in a timely manner | 99.8 | 95.7 |
How often the home health team taught patients (or their family caregivers) about their drugs | 99.8 | 98.6 |
How often the home health team checked patients’ risk of falling | 100 | 99.6 |
How often the home health team checked patients for depression | 99.8 | 97.4 |
How often the home health team made sure that their patients have received a flu shot for the current flu season. | 91.3 | 78.7 |
How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 98 | 82.2 |
With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 99.4 | 96.4 |
News Archive
Gilead Sciences, Inc. and Arresto Biosciences, Inc., a privately-held, development-stage biotechnology company focused on medicines to treat fibrotic diseases and cancer, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Arresto. Under the terms of the agreement, Gilead will acquire Arresto for $225 million and potential future payments based on achievement of certain sales levels.
Disorders of blood cells may begin in the biological environment where the cells develop, not just with the cells themselves, according to a study from researchers at the Massachusetts General Hospital (MGH) and the Peter MacCallum Cancer Center (Peter Mac) in Melbourne, Australia.
Food advertising is a multi-billion dollar industry, with approximately $1.8 billion annually aimed at children and adolescents, who view between 1,000 and 2,000 ads per year.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).
Peripheral artery disease (PAD) is a progressive and costly disease, but remains under-diagnosed and under treated. While current PAD treatments are effective at clearing artery blockages in the lower leg, high recurrence rates and the subsequent need for repeat procedures are costly. Even after initial procedures to clear blockages in leg arteries, hospitalizations and associated costs in patients with peripheral artery disease increase as the condition progresses, according to research reported in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
› Verified 3 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often patients got better at walking or moving around | 87.6 | 79.6 |
How often patients got better at getting in and out of bed | 86 | 81.1 |
How often patients got better at bathing | 88.4 | 82.3 |
How often patients’ breathing improved | 85.5 | 82.8 |
How often patients’ wounds improved or healed after an operation | 95.6 | 92.3 |
How often patients got better at taking their drugs correctly by mouth | 79.5 | 75 |
How often home health patients had to be admitted to the hospital | 18.5 | 15.4 |
How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 17.5 | 13 |
How often physician-recommended actions to address medication issues were completely timely | 99.3 | 94 |
News Archive
Gilead Sciences, Inc. and Arresto Biosciences, Inc., a privately-held, development-stage biotechnology company focused on medicines to treat fibrotic diseases and cancer, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Arresto. Under the terms of the agreement, Gilead will acquire Arresto for $225 million and potential future payments based on achievement of certain sales levels.
Disorders of blood cells may begin in the biological environment where the cells develop, not just with the cells themselves, according to a study from researchers at the Massachusetts General Hospital (MGH) and the Peter MacCallum Cancer Center (Peter Mac) in Melbourne, Australia.
Food advertising is a multi-billion dollar industry, with approximately $1.8 billion annually aimed at children and adolescents, who view between 1,000 and 2,000 ads per year.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).
Peripheral artery disease (PAD) is a progressive and costly disease, but remains under-diagnosed and under treated. While current PAD treatments are effective at clearing artery blockages in the lower leg, high recurrence rates and the subsequent need for repeat procedures are costly. Even after initial procedures to clear blockages in leg arteries, hospitalizations and associated costs in patients with peripheral artery disease increase as the condition progresses, according to research reported in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
› Verified 3 days ago
Question Type: | Rating by Patients |
---|---|
Health team gave care in a professional way | |
Health team communicated well with them | |
Health team discussed medicines, pain, and home safety | |
How patients rated overall care from agency |
News Archive
Gilead Sciences, Inc. and Arresto Biosciences, Inc., a privately-held, development-stage biotechnology company focused on medicines to treat fibrotic diseases and cancer, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Arresto. Under the terms of the agreement, Gilead will acquire Arresto for $225 million and potential future payments based on achievement of certain sales levels.
Disorders of blood cells may begin in the biological environment where the cells develop, not just with the cells themselves, according to a study from researchers at the Massachusetts General Hospital (MGH) and the Peter MacCallum Cancer Center (Peter Mac) in Melbourne, Australia.
Food advertising is a multi-billion dollar industry, with approximately $1.8 billion annually aimed at children and adolescents, who view between 1,000 and 2,000 ads per year.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).
Peripheral artery disease (PAD) is a progressive and costly disease, but remains under-diagnosed and under treated. While current PAD treatments are effective at clearing artery blockages in the lower leg, high recurrence rates and the subsequent need for repeat procedures are costly. Even after initial procedures to clear blockages in leg arteries, hospitalizations and associated costs in patients with peripheral artery disease increase as the condition progresses, according to research reported in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
› Verified 3 days ago
The patient survey data of Capital Health Home Care is compared against the national average with the color code indicators: Better than National Average Worse than National AverageExperience Measure | Provider | National Avg. |
---|---|---|
Percent of patients who reported that their home health team gave care in a professional way | 90 | 88 |
Percent of patients who reported that their home health team communicated well with them | 89 | 85 |
Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 82 | 83 |
Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 86 | 84 |
Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 81 | 78 |
News Archive
Gilead Sciences, Inc. and Arresto Biosciences, Inc., a privately-held, development-stage biotechnology company focused on medicines to treat fibrotic diseases and cancer, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Arresto. Under the terms of the agreement, Gilead will acquire Arresto for $225 million and potential future payments based on achievement of certain sales levels.
Disorders of blood cells may begin in the biological environment where the cells develop, not just with the cells themselves, according to a study from researchers at the Massachusetts General Hospital (MGH) and the Peter MacCallum Cancer Center (Peter Mac) in Melbourne, Australia.
Food advertising is a multi-billion dollar industry, with approximately $1.8 billion annually aimed at children and adolescents, who view between 1,000 and 2,000 ads per year.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).
Peripheral artery disease (PAD) is a progressive and costly disease, but remains under-diagnosed and under treated. While current PAD treatments are effective at clearing artery blockages in the lower leg, high recurrence rates and the subsequent need for repeat procedures are costly. Even after initial procedures to clear blockages in leg arteries, hospitalizations and associated costs in patients with peripheral artery disease increase as the condition progresses, according to research reported in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
› Verified 3 days ago
Ashtabula Regional Home Health Location: 2131 Lake Avenue, Suite 2, Ashtabula, Ohio 44004 Ratings: Phone: (440) 994-7652 | |
Capital Health Home Care Location: 1100 Lake Avenue, Ashtabula, Ohio 44004 Ratings: Phone: (440) 964-0444 | |
Peace And Serenity Home Health Care Llc Location: 925 East 26th Street, Ashtabula, Ohio 44004 Ratings: Phone: (440) 536-4803 |